TAK - Neurocrine succeeds in mid-stage trial for Takeda-partnered depression drug
2024-04-23 14:22:14 ET
More on Neurocrine Biosciences
- Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
- Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript
- Sentia Medical Sciences and Neurocrine Biosciences extend research collaboration
- Neurocrine Biosciences Q4 2023 Earnings Preview
- Seeking Alpha’s Quant Rating on Neurocrine Biosciences